Literature DB >> 22635006

Development of a new hydrogen peroxide–based vaccine platform.

Ian J Amanna1, Hans-Peter Raué, Mark K Slifka.   

Abstract

Safe and effective vaccines are crucial for maintaining public health and reducing the global burden of infectious disease. Here we introduce a new vaccine platform that uses hydrogen peroxide (H(2)O(2)) to inactivate viruses for vaccine production. H(2)O(2) rapidly inactivates both RNA and DNA viruses with minimal damage to antigenic structure or immunogenicity and is a highly effective method when compared with conventional vaccine inactivation approaches such as formaldehyde or β-propiolactone. Mice immunized with H(2)O(2)-inactivated lymphocytic choriomeningitis virus (LCMV) generated cytolytic, multifunctional virus-specific CD8(+) T cells that conferred protection against chronic LCMV infection. Likewise, mice vaccinated with H(2)O(2)-inactivated vaccinia virus or H(2)O(2)-inactivated West Nile virus showed high virus-specific neutralizing antibody titers and were fully protected against lethal challenge. Together, these studies demonstrate that H(2)O(2)-based vaccines are highly immunogenic, provide protection against a range of viral pathogens in mice and represent a promising new approach to future vaccine development.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22635006      PMCID: PMC3506259          DOI: 10.1038/nm.2763

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  34 in total

1.  Antigenicity of beta-propiolactone-inactivated virus vaccines.

Authors:  G A LOGRIPPO; F W HARTMAN
Journal:  J Immunol       Date:  1955-08       Impact factor: 5.422

Review 2.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  Antiviral cytotoxic T-cell memory by vaccination with recombinant Listeria monocytogenes.

Authors:  M K Slifka; H Shen; M Matloubian; E R Jensen; J F Miller; R Ahmed
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

Review 6.  Review of accidents caused by incomplete inactivation of viruses.

Authors:  F Brown
Journal:  Dev Biol Stand       Date:  1993

7.  Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

Authors:  D E Hassett; M K Slifka; J Zhang; J L Whitton
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Equine vaccine for West Nile virus.

Authors:  T Ng; D Hathaway; N Jennings; D Champ; Y W Chiang; H J Chu
Journal:  Dev Biol (Basel)       Date:  2003

9.  Monkeypox virus evades antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation.

Authors:  Erika Hammarlund; Anindya Dasgupta; Clemencia Pinilla; Patricia Norori; Klaus Früh; Mark K Slifka
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-16       Impact factor: 11.205

10.  Behavioral risks for West Nile virus disease, northern Colorado, 2003.

Authors:  Indira B Gujral; Emily C Zielinski-Gutierrez; Adrienne LeBailly; Roger Nasci
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

View more
  50 in total

Review 1.  Current trends in West Nile virus vaccine development.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Expert Rev Vaccines       Date:  2014-04-01       Impact factor: 5.217

Review 2.  Raising expectations for subunit vaccine.

Authors:  John T Schiller; Douglas R Lowy
Journal:  J Infect Dis       Date:  2014-11-24       Impact factor: 5.226

3.  Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates.

Authors:  Andrea Marzi; Peter Halfmann; Lindsay Hill-Batorski; Friederike Feldmann; W Lesley Shupert; Gabriele Neumann; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  Science       Date:  2015-03-26       Impact factor: 47.728

4.  Characterization of humoral and cellular immune features of gamma-irradiated influenza vaccine.

Authors:  Fengjia Chen; Ho Seong Seo; Hyun Jung Ji; Eunji Yang; Jung Ah Choi; Jae Seung Yang; Manki Song; Seung Hyun Han; Sangyong Lim; Jae Hyang Lim; Ki Bum Ahn
Journal:  Hum Vaccin Immunother       Date:  2020-07-09       Impact factor: 3.452

5.  Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine.

Authors:  Joshua M Walker; Hans-Peter Raué; Mark K Slifka
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

6.  Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine.

Authors:  Benjamin K Quintel; Archana Thomas; Danae E Poer DeRaad; Mark K Slifka; Ian J Amanna
Journal:  Vaccine       Date:  2018-12-31       Impact factor: 3.641

7.  A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice.

Authors:  Amelia K Pinto; Justin M Richner; Elizabeth A Poore; Pradnya P Patil; Ian J Amanna; Mark K Slifka; Michael S Diamond
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

8.  Development of an algorithm for production of inactivated arbovirus antigens in cell culture.

Authors:  C H Goodman; B J Russell; J O Velez; J J Laven; W L Nicholson; D A Bagarozzi; J L Moon; K Bedi; B W Johnson
Journal:  J Virol Methods       Date:  2014-08-04       Impact factor: 2.014

9.  Antiviral immune response after live yellow fever vaccination of a kidney transplant recipient treated with IVIG.

Authors:  Mark K Slifka; Erika Hammarlund; Matthew W Lewis; Elizabeth A Poore; Jon M Hanifin; Kieren A Marr; Douglas Hecox; Ian J Amanna
Journal:  Transplantation       Date:  2013-05-15       Impact factor: 4.939

10.  The Nucleoprotein Is Required for Lymphocytic Choriomeningitis Virus-Based Vaccine Vector Immunogenicity.

Authors:  Stephanie Darbre; Susan Johnson; Sandra Kallert; Paul-Henri Lambert; Claire-Anne Siegrist; Daniel D Pinschewer
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.